A Study of RO5458640 in Patients With Advanced Solid Tumors

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically confirmed malignant solid tumors * Measurable and/or evaluable disease according to RECIST 1.1 criteria * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Adequate bone marrow, liver and renal function Exclusion Criteria: * Prior chemotherapy, radiotherapy, or hormonal therapy for cancer within 3 weeks of first study treatment, except for short course palliative radiotherapy for pain * Antibody therapy or other immunotherapy currently or less than 21 days prior to study treatment * Current immunosuppressive therapy, including those prescribed for organ transplantation and rheumatologic disease * Corticoid therapy \> 10 mg/day prednisone or equivalent * Patients who have not recovered from \> grade 1 (NCI CTCAE) prior adverse events from any cancer therapy, except for alopecia * Pregnant or breastfeeding women * Known hypersensitivity to any component of RO5458640 or previous severe hypersensitivity reactions to monoclonal antibody therapy * History of active seizure disorder * History of CNS or leptomeningeal metastases, except for clinically stable disease for at least 3 weeks prior to first study drug * Cardiovascular illness: CVA or MI \< 6 months prior to study, CHF \> NYHA Class 2, QTcF \>480 msec. * Active infection